关爱生命 呵护健康

All for Health Health for All

传承百年护佑生命

Hundred Years Inheritance in Protecting Life

北京生物制品研究所有限责任公司
Beijing Institute of Biological Products Co.,Ltd.
地址：北京经济技术开发区博兴二路6号
Address:No.6 Bo xing 2n Road,Economic-Technological Development Area,Beijing

北京生物官方公众号

北京生物官方视频号

中国生物 CNBG

国药集团 SGPHARM

北京生物制品研究所有限责任公司

BEUING INSTITUTE OF BIOLOGICAL PRODUCTS CO.,LTD.

中国生物 CNBG

公司简介

Company Introduction

北京生物制品研究所有限责任公司（简称“北京生物”）是中国医药集团有限公司旗下，从事疫苗与诊断制剂等生物制品研究、生产、销售的高新技术企业。公司控股股东为中国生物技术股份有限公司，公司历史可以追溯到1919年，是中国生物制品行业的摇篮。百年以来，公司始终秉承“关爱生命，呵护健康”的企业发展理念，致力于消灭天花，消除麻疹，维持无脊灰状态，降低乙肝病毒携带率，控制儿童百日咳、白喉、破伤风等传染病。

在新冠疫情蔓延全球之际，北京生物积极践行打造“人类卫生健康共同体”的理念精神，奋战98天成功研制新冠灭活疫苗并启动国际临床试验。2020年12月9日，北京生物研制的新型冠状病毒灭活疫苗（Vero 细胞）在阿联酋正式注册上市；2021年4月1日，获得欧盟GMP 认证与使用许可；2021年5月7日，获得世卫组织紧急使用授权，并纳入全球新冠疫苗“紧急使用清单”，成为中国首个被纳入世卫组织紧急使用清单的新冠疫苗和全球首个被纳入世卫组织紧急使用清单的新冠灭活疫苗。截至目前，北京生物研制的新冠灭活疫苗已在119个国家、地区及国际组织获批注册上市或紧急使用，接种人群覆盖196个国别，国内外累计生产供应达35亿剂。

Beijing Institute of Biological Products Co.,Ltd.(BIBP)is a high-tech enterprise subordinated to China National Pharmaceutical Group Co.,Ltd.(Sinopharm),engaged in research,manufacturing and marketing of biological products including vaccines and diagnostic kits.It's the cradle of new China's biological industry with over one hundred year's history that can be traced back to 1919. Over the past hundred years,BIBP has always been adhering to the development concept of"All for Health, Health for All",and commiting to eradicating smallpox, eliminating measles,maintaining polio-free status,reducing the carrier rate of hepatitis B virus,and controlling children's pertussis,diphtheria,tetanus and other infectious diseases.

As the COVID-19 spreads around the world,BIBP actively *practiced the spirit of "Building a Global Communityof* Health for All",and quickly developed the Inactivated COVID-19 Vaccine (Vero Cell)and conducted international multi-center clinical trials.On December9,2020,BIBP's COVID-19 vaccine was officially registered and marketed in the United Arab Emirates.OnApril 1,2021,BIBP obtained EU GMP certificate.On May 7,2021,the COVID-19 vaccine was listed in WHO emergency use listing(EUL),becoming China's first COVID-19 vaccine and world's first inactivated COVID-19 vaccine in WHO EUL.Upto now,BIBPs COVID-19 vaccine has been approved for marketing authorization or emergency use in 119countries,regions or international organizations around the world,protecting people from 196 different countries,with a total supply of 3.5 billion doses.

中国生物 CNBG
国药集团 SINOPHARM

新冠灭活疫苗研发极限挑战

Great Challenge for R&D of Inactivated COVID-19 Vaccine

同时间赛跑与病毒较量

Race against time and battle against virus

北京生物制品研究所的新冠疫苗项目研发团队，关键时刻他们责无旁贷、义无反顾，凝心聚力、奋力一搏，为助力全球战胜疫情贡献中国方案和中国力量。

The COVID-19 vaccine R&D team of BIBP is obliged and duty-bound,at the critical moment,to proceed without hesitation and workday and night to contribute China's solutions and power to overcoming the epidemic all over the world.

中国生物 CNBG
国药集团 SINOPHARM

突破创新面向国际

Breakthrough Innovation
Facing International

一座具有前沿性、规模性、集约性的研发大楼和联合研发中心，为推进北京生物科技创新，实现开放式创

新格局，服务国家重大战略需求，提供强有力的支撑，也为广大生物医药人才，提供了更广阔的空间。

A state-of-the-art design and cutting-edge R&D building,also a joint R&D center,provides concrete support for promoting scientific innovation, building an open innovation landscape,and meeting the major national strategic needs.It also offers more opportunities for biotech talents.

中国生物 CNBG

国药集团 SINOPHARM

企业理念

Company Philosophy

传承百年护佑生命

Hundred Years Inheritance in Protecting Life

北京生物制品研究所秉承着以科学严谨为底色，以创新为驱动力，传承百年精神，肩负人民使命，始终坚持做公共卫生安全的支撑者、科技创新发展的引领者、国家责任的担当者。

BIBP adheres to the principles of being scientific,rigorous and innovation driven,with hundred year's inheritance of protecting life,shoulders the mission of the people,and always acts as the supporter of public health and security,as the leader in scientific and technological innovation and development,and as the bearer of national responsibility.

中国生物 CNBG
国药集团 SINOPHARM

产品介绍

Product introduction

新型冠状病毒灭活疫苗（Vero 细胞）

COVID-19 Vaccine (Vero Cell),Inactivated

2020年12月31日附条件上市，为全病毒疫苗。**基于自主研发生产的300升篮式反应器，运用成熟的高密度细胞培养专利技术，具有极高安全性和有效性，且易于存储和运输。**为首个全球上市的中国新冠疫苗、通过WHO 认证的非西方国家新冠疫苗、欧盟GMP 认证的中国新冠疫苗。北京生物的新冠疫苗在119个国家、地区及国际组织获准使用。

COVID-19 Vaccine (Vero Cell),Inactivated is a whole-virus vaccine,which was conditionally approved for marketing on December 31,2020 in China.It is based on self-developed 300-L basket bioreactor,and uses mature patented technology of high-density cell culture.The product is extremely safe and effective,and easy to store and transport.It was listed in WHO emergency use listing (EUL),becoming China's first COVID-19 vaccine and world's first inactivated COVID-19 vaccine in WHO EUL.Up to now,BIBP's COVID-19 vaccine has been approved for marketing authorization or emergency use in 119 countries,regions or international organizations around the world.

中国生物
CNBG
国药集团
SINOPHARM

Sabin 株脊髓灰质炎灭活疫苗(Vero 细胞)

Poliomyelitis Vaccine (Vero Cell), Inactivated,Sabin Strains (sIPV)

2017年9月7日正式获批上市。为三价疫苗，保护率高，质量稳定、不良反应率低。为完全自主知识产权疫苗，获得北京市新技术新产品证书。于2022年获得WHO 预认证，同bOPV 一起，持续为全球消灭脊灰计划作出贡献。

sIPV was approved for marketing on September 7,2017.As the trivalent vaccine,it has high protection rate,stable quality and low incidence of adverse reaction.sIPV is a vaccine with intellectual property rights fully owned by BIBP,and acquired the Beijing New Technology and New Product Certificate.It obtained WHO prequalification in 2022,and will continue to contribute to the Global Polio Eradication Initiative together with BIBP's bOPV which has already been worldwide used.

中国生物 CNBG
国药集团 SINOPHARM

黄热减毒活疫苗

Vellow Fever Vaccine,Live (YFV)

1953年上市，国内唯一供应。产品是除菌过滤工艺，单人份制剂，全程无任何抗生素添加。收录于2020版药典，满足WHO TRS 978及EP 10.0质控标准，领先国际水平。2017年通过WHO 预认证现场核查。

YFV was approved for marketing in 1953,and BIBP is the only manufacturer in China.YFV is a single dose product developed through sterilization fitration process without any antibiotics added in the whole process.It's a world-leading product and was included in the Chinese Pharmacopoeia 2020 in line with the quality control standards specified in WHO TRS 978 and European Pharmacopoeia 10.0.YFV passed WHO prequalfication on-site inspection in 2017.

中国生物 CNBG



麻腮风联合减毒活疫苗-

Measles,Mumps and Rubella Combined Vaccine,Live (MMR)

2002年上市。使用的风疹毒株为自主研发的风疹毒种BRDⅡ株，所用的细胞为自主研发的人二倍体细胞；使用细胞工厂培养原代鸡胚细胞、人二倍体细胞及麻疹、腮腺炎、风疹病毒，为国内首家采用细胞工厂工艺的麻腮风疫苗上市产品。2003年被认定为北京市重大高新技术成果转化项目；2004年被认定为国家重点新产品。

MMR was approved for marketing in 2002.It uses the rubella virus seed BRDll strain and human diploid cell which both are independently developed by BIBP.It was the first product in China to adopt cell factory technology to culture the original chicken embryo cell,human diploid cell as well as the viruses of measles,mumps and rubella.It was accredited as the major high-tech achievement transformation project in Beijing in 2003,and as the national key new product in 2004.

口服Ⅰ型Ⅲ型脊髓灰质炎减毒活疫苗（人二倍体细胞）

Poliomyelitis (Live)Vaccine Type Ⅰ Type Ⅲ (Human Diploid Cell),Oral (bOPv)

2015年11月19日获得药品注册批件，2016年5月1日正式投放市场。bOPV 为口服无菌制剂，采用细胞工厂工艺生产，具有生产占用空间小、易于实现标准化操作、质量更加均一、稳定等优点。于2017年12月21日通过了世卫组织预认证，并已完成了多国的国际注册。加入了UNICEF 的采购名录，产品已发往南苏丹、埃及、津巴布韦等多个国家，累计发货超过1亿剂次，为全球消灭脊髓灰质炎贡献一份力量。

With the Certificate of Drug Registration obtained on November 19,2015,bOPv was officially launched to the market on May 1, 2016.As an oral sterile vaccine,bOPV is manufactured through cell factory process which leads to better quality and stability.This product passed WHO prequaliffication on December 21,2017 and has obtained marketing authorization in multiple countries. It was listed in the UNICEF purchase list,and up to now,over 100 million doses have been shipped to South Sudan,Egypt,Zimbabwe and other countries,making a great contribution to the ambitious goal of Global Polio Eradication Initiative.